3 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Epilepsy, Absence: new trials by email Literature Review of Epilepsy, Absence trials Research Report on Epilepsy, Absence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Active not recruiting | UCB Biopharma SRL | 70 | 2024-07-10 | 2026-08-27 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures BHV-7000, Placebo - Generalized Epilepsy | Phase 2 / Phase 3 | Terminated | Biohaven Therapeutics Ltd. | 27 | 2024-06-20 | 2026-03-24 |
| A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Completed | UCB Biopharma SRL | 84 | 2022-03-30 | 2025-10-22 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam, Placebo - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Completed | UCB Biopharma SRL | 154 | 2021-07-29 | 2026-10-30 |
| Ketogenic Diet for New-Onset Absence Epilepsy Modified Atkins Diet, Absence epilepsy medications - Absence Epilepsy, Ketogenic Dieting | Phase 3 | Recruiting | Johns Hopkins University | 40 | 2020-08-10 | 2026-05-07 |
| Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study Ethosuximide, Lamotrigine, Valproic acid - Childhood Absence Epilepsy, Petit Mal Epilepsy | Phase 3 | Completed | Children's Hospital Medical Center, Cincinnati | 453 | 2004-07-01 | 2020-10-14 |
Epilepsy (4) · Seizures (2) · Drug Resistant Epilepsy (1) · Epilepsy, Generalized (1) · Epilepsy, Idiopathic Generalized (1) · Myoclonic Epilepsy, Juvenile (1)
Brain Diseases (6) · Central Nervous System Diseases (6) · Epileptic Syndromes (6) · Nervous System Diseases (6) · Epilepsy, Generalized (5) · Epilepsy (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Epilepsies, Myoclonic (1)
brivaracetam (3) · Ethosuximide (2) · Lamotrigine (2) · Valproic Acid (2)
UCB Biopharma SRL (3) · Biohaven Therapeutics Ltd. (1) · Children's Hospital Medical Center, Cincinnati (1) · Johns Hopkins University (1)
United States (6) · Italy (4) · Georgia (3) · Romania (3) · Slovakia (3) · Spain (2) · Ukraine (2) · Australia (1) · Austria (1) · Belgium (1) · Croatia (1) · Finland (1) · France (1) · Germany (1) · Netherlands (1)
Avital Cnaan, PhD (1) · Eric H Kossoff, MD (1) · Peter Adamson, MD (1) · Tracy A. Glauser, MD (1)
PMID 20200383, PMID 28916534, PMID 35844134
2023 (3), U01NS045803 (1)